Marijuana research may reach new heights as Trump Administration reclassifies medical cannabis

The Trump Administration is changing federal cannabis policy. On Thursday acting Attorney General Todd Blanche signed an order reclassifying medical marijuana from a Schedule I to a Schedule III drug.  That puts the drug in the same category as substances like ketamine and anabolic steroids. Now, this doesn’t mean cannabis is legal nationwide, and people with convictions related to marijuana won’t see their charges dropped. But officials say it’ll allow for more research into cannabis for medical use. For distributors in the 40 states that have medical marijuana systems already in place, it could mean tax benefits and less hoops to jump through when selling cannabis. This reclassification does not impact recreational marijuana. But advocates say it could be a sign of bigger changes to come. Guest:  Dr. Susan Ferguson, Director of the Addictions, Drug & Alcohol Institute at the University of Washington Related links: Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III, Strengthening Medical Research While Maintaining Strict Federal Controls Federal Marijuana Rescheduling Will End Discrimination In Housing, Healthcare And Employment For Medical Cannabis Patients (Op-Ed) - Marijuana Moment SAM CONDEMNS IN THE STRONGEST POSSIBLE TERMS THE TRUMP ADMINISTRATION’S ILLEGAL DIRECTIVE ON MARIJUANA RESCHEDULING - Smart Approaches to Marijuana Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.